Prot #VX17-445-105: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date7/29/18 → 7/29/26

Funding

  • Greenphire, Inc. ((OE) Prot #VX17-445-105 // (OE) Prot #VX17-445-105)
  • Vertex Pharmaceuticals Incorporated ((OE) Prot #VX17-445-105 // (OE) Prot #VX17-445-105)